Global circulatingtumor cells market is anticipated to reach USD 11,552.3 million
by 2022, according to a new report by Grand View Research, Inc. Rising
developments in the field of biomedical engineering and biomedical imaging
coupled with rise in patented research initiatives by the government is
expected to drive this industry through the forecast period.
Introduction of novel
technologies for enumeration of circulating tumor cells is anticipated to fuel
growth in this sector through to 2022. Furthermore, increasing incidences of
chronic oncology diseases that depend on the detection and analysis of CTCs, as
it has enormous potential in the real-time monitoring of cancer therapy,
over the conventional methods such as imaging technologies and tumor tissue
biopsy.
Additionally, application of
CTC as biomarkers for drug discovery is a promising factor for growth in the
coming years. Utilization of the circulating tumor cells in development of
tumor specific biomarkers in order to optimize the selection of targeted
therapies and assessment of better response to the therapy is expected to
support in the projected growth of CTC market in the coming years.
Access Full Research
Report On Circulating Tumor Cells Market Analysis:
www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market
www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market
Further key findings from the study suggest:
·
CTC enrichment accounted for
the largest share of market revenue in 2014 and is expected to continue this
dominance owing to high usage rates in oncology research establishments and
high accuracy exhibited by this technology.
·
Microchips technology is
anticipated to register substantial growth in the next seven years because of
the introduction of cluster chip technology that enables capture of clusters of
tumor cells for CTC quantitation.
·
Characteristic property of the
cancer stem cells of self-renewal in replenishing the growing cancer is driving
the attention of organizations and researchers in CTC cancer stem cell research
segment thus accounting for the segment’s large share in revenue generation.
·
Application of alterations
witnessed in the expression profiles of EMT-associated transcriptional
regulators and their molecular targets as biomarkers in EMT study is expected
to serve as an impetus for diagnosis of tumour recurrence consequently driving
the segment with a double digit CAGR of over 10%.
·
North America dominated the
market in 2014, with revenue estimation that accounted for over 45% of the
global market. Presence of strong oncology research funding, refined healthcare
infrastructure, growing incidence of cancer, favorable government initiatives
with respect to R&D funding for clinical diagnostic products are factors
attributive for larger revenue share.
·
Asia Pacific is anticipated to
witness lucrative CAGR of over 16% as a result of infrastructure development in
care centers coupled with increase in sales of CTC diagnostic tests. The need
of new diagnosis methods for the growing cancer cases has gushed up research on
new developments in developing economies of this region thus providing
potential avenues for market growth.
·
Key participants of CTC
industry include Canopus Biosciences, Clearbridge BioMedics, Fluxion
Biosciences, Janssen Diagnostics, Adnagen, Advanced Cell Diagnostics, Apocell,
Vitatex Inc., Miltenyi Biotech Cynvenio Biosystems, Aviva Biosciences, Biocept
Inc., Biofluidica, Creatv Microtech Inc., Ikonisys Inc., Epic Biosciences,
Biocep Ltd., Greiner Bio-one GmbH, Sysmex Corporation, and CellTraffix Inc.
·
These market entities are
involved in collaborations with hospitals and university based research
institutes in order to gain access to target population and develop novel
technologies for CTC enrichment & detection.
Browse More Reports Of This Category By
Grand View Research At: www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented
circulating tumor cells market on the basis of technology, application, and
region:
Global Circulating Tumor
Cell Technology Outlook (Revenue, USD Million, 2012 - 2022)
·
CTC Enrichment
o Ex-vivo positive selection
o In-vivo positive selection
o
Negative selection
o
Microchips
o
Single spiral micro channel
·
CTC Detection
o
Immunocytochemical technologies
o
Molecular(RNA) based
technologies
o EPISPOT functional in-vitro cell
culture
o Functional in-vitro cell
invasion assay
o
Xenotransplantation models
·
CTC Analysis
Global Circulating Tumor Cell
Application Outlook (Revenue, USD Million, 2012 - 2022)
·
Tumorigenesis research
·
EMT biomarkers development
·
Cancer stem cell research
·
Others
Circulating Tumor Cell Regional
Outlook (Revenue, USD Million, 2012 - 2022)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
France
o
UK
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
·
MEA
o
South Africa
Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-circulating-tumor-cells-market
www.grandviewresearch.com/press-release/global-circulating-tumor-cells-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more information: www.grandviewresearch.com/
